82 3 2850 5000
|Mr. Hyong-Gi Kim||CEO & Internal Director||N/A||N/A||1965|
|Mr. Woo-Sung Kee||CEO & Internal Director||N/A||N/A||1961|
|Mr. Stephen Yeum||Founder||N/A||N/A||N/A|
|Mr. Min-Cheol Shin||Director of Fin.||N/A||N/A||1971|
|Mr. Ji-Hoon Choi||Director of Legal Affairs||N/A||N/A||1971|
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 3 clinical trial; CT-P17 for the treatment of autoimmune diseases which is in phase 3 clinical trial; CT-P16 for the treatment of non-small cell lung cancer and colon cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 3 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P47 for the treatment of rheumatoid arthritis, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. The company was founded in 2002 and is headquartered in Incheon, South Korea.
Celltrion, Inc.s ISS Governance QualityScore, Stand 1. Juni 2023, lautet 3. Die grundlegenden Scores sind Audit: 10, Vorstand: 4, Shareholderrechte: 1, Kompensation: 1.